CLAIMS:

1. A composition comprising a polypeptide comprising the amino acid sequence in SEQ ID NO: 6; wherein the methionine residue at position 1 of SEQ ID NO: 6 is not present, wherein a lysine residue of the polypeptide is crosslinked to a beta-alanine moiety; and a pharmaceutically acceptable diluent.

2. The composition according to claim 1, wherein an aspartic acid residue of the polypeptide is crosslinked to a glycine moiety.

3. The composition according to claim 1, wherein a glutamic acid residue of the polypeptide is crosslinked to a glycine moiety.

4. The composition according to claim 1, wherein a second lysine residue of the polypeptide is crosslinked to an aspartic acid residue of the polypeptide.

5. The composition according to claim 1, wherein a second lysine residue of the polypeptide is crosslinked to a glutarnic acid residue of the polypeptide.

6. The composition according to claim 1, wherein the polypeptide further comprises a dehydroalanine moiety.

7. The composition according to claim 1; wherein the composition is immunogenic.

8. The composition according to claim 1, wherein the composition is lyophilized.

9. The composition according to claim 1, wherein the composition further comprises an adjuvant.

10. The composition according to claim 1, wherein the composition further comprises aluminum hydroxide.

11. The composition according to claim 1, wherein the composition does not further comprise an adjuvant.

12. The composition according to claim 1, wherein the composition further comprises trehalose.

13. The composition according to claim 1, wherein the composition further comprises polysorbate-80.

14. The composition according to claim 1, wherein the composition further comprises a saponin adjuvant.

15. The composition according to claim 1, wherein the composition further comprises a CpG oligonucleotide.

16. The composition according to claim 1, wherein the composition further comprises aluminum hydroxide gel and a CpG oligonucleotide.

17. The composition according to claim 1, wherein the composition further comprises Tris buffer.

18. The composition according to claim 1, wherein the composition does not further comprise formaldehyde.

19. The composition according to claim 1, wherein the composition further comprises a toxoid of *Clostridium difficile* toxin A.

20. The composition according to claim 1, wherein the pH of the composition is 5.5-8.0.